These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25370322)

  • 1. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
    Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
    Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
    Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
    Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials.
    Kapur R; Mittra S; Tonpe G; P A; Raj P; Gudat U; Athalye SN
    Expert Opin Biol Ther; 2024 Jun; 24(6):543-561. PubMed ID: 38934226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
    van Bon AC; Bode BW; Sert-Langeron C; DeVries JH; Charpentier G
    Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD; Marcus AO; Weng CS; Howard CP; Schorr AB;
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Gonzalez-Padilla DA
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011281. PubMed ID: 26798030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study.
    Melidonis A; Kamaratos A; Angelidi A; Thomakos P; Vrakas S; Bakalis J; Fousteris E; Iraklianou S
    Diabetes Technol Ther; 2016 Mar; 18(3):159-63. PubMed ID: 26862678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus.
    Kaiserman K; Rodriguez H; Stephenson A; Wolka L; Fahrbach JL
    Endocr Pract; 2012; 18(3):418-24. PubMed ID: 22297055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
    Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
    Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    ; Russell SJ; Beck RW; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Calhoun P; Wadwa RP; Buckingham B; Zhou K; Daniels M; Raskin P; White PC; Lynch J; Pettus J; Hirsch IB; Goland R; Buse JB; Kruger D; Mauras N; Muir A; McGill JB; Cogen F; Weissberg-Benchell J; Sherwood JS; Castellanos LE; Hillard MA; Tuffaha M; Putman MS; Sands MY; Forlenza G; Slover R; Messer LH; Cobry E; Shah VN; Polsky S; Lal R; Ekhlaspour L; Hughes MS; Basina M; Hatipoglu B; Olansky L; Bhangoo A; Forghani N; Kashmiri H; Sutton F; Choudhary A; Penn J; Jafri R; Rayas M; Escaname E; Kerr C; Favela-Prezas R; Boeder S; Trikudanathan S; Williams KM; Leibel N; Kirkman MS; Bergamo K; Klein KR; Dostou JM; Machineni S; Young LA; Diner JC; Bhan A; Jones JK; Benson M; Bird K; Englert K; Permuy J; Cossen K; Felner E; Salam M; Silverstein JM; Adamson S; Cedeno A; Meighan S; Dauber A
    N Engl J Med; 2022 Sep; 387(13):1161-1172. PubMed ID: 36170500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
    Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
    Watada H; Imori M; Li P; Iwamoto N
    Endocr J; 2017 Jul; 64(7):705-717. PubMed ID: 28539526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.